REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT

摘要

Vascular endothelial growth factor plays an important role in the development of abnormal blood vessels in proliferative diabetic retinopathy and other retinovascular diseases. Intravitreal administration of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA), a humanized monoclonal antibody to vascular endothelial growth factor, has recently been reported to be of benefit in macular degeneration. This case report demonstrates the rapid resolution of iris and retinal neovasculariza-tion in a diabetic patient after the intravitreal injection of bevacizumab.